PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer

The International Journal of Biological Markers
Sensen ChengJie Liu

Abstract

PD-1 and its ligand PD-L1 belong to the co-inhibition molecules, which can downregulate immune responses. The PD-L1 polymorphism and the level of soluble PD-L1 (sPD-L1) were investigated in non-small cell lung cancer (NSCLC). A total of 288 NSCLC patients and 300 controls were enrolled. An A/C polymorphism at position 8923 in the PD-L1 gene was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method. The prevalence of the 8923C allele was significantly higher in NSCLC patients than controls (10.2% versus 5.3%, p = 0.002, odds ratio 2.03, 95% confidence interval 1.30-3.17; data were adjusted for age and sex). NSCLC patients also showed increased plasma levels of sPD-L1 compared to controls (1.92 ng/mL versus 0.91 ng/mL, p<0.001). Furthermore, lung adenocarcinoma patients had higher sPD-L1 levels than patients with squamous cell carcinoma (p<0.01). However, no association was observed between the different genetic variants and plasma concentrations of sPD-L1. The PD-L1 8923A/C polymorphism could be associated with increased susceptibility to NSCLC. Plasma levels of sPD-L1 are significantly increased in NSCLC patients, especially those with adenocarcinoma.

References

May 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M K Oaks, K M Hallett
Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Dec 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bing WanJingwu Z Zhang
Jul 1, 2008·Molecular Immunology·Manish J ButteArlene H Sharpe
Sep 3, 2009·Biochemical and Biophysical Research Communications·Yosuke KamimuraMiyuki Azuma
Oct 24, 2009·The Journal of Clinical Endocrinology and Metabolism·Anna L MitchellSimon H S Pearce
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Mar 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xavier FrigolaEugene D Kwon
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario Sznol, Lieping Chen
Mar 21, 2013·British Journal of Cancer·S A Quezada, K S Peggs
Nov 13, 2013·Laboratory Investigation; a Journal of Technical Methods and Pathology·Vamsidhar VelchetiDavid L Rimm
May 13, 2014·Diabetes/metabolism Research and Reviews·Carolina PizarroFrancisco Pérez-Bravo
Oct 29, 2014·British Journal of Cancer·A D'InceccoF Cappuzzo

❮ Previous
Next ❯

Citations

Dec 24, 2018·American Journal of Reproductive Immunology : AJRI·Li-Ling WangAi-Hua Liao
Jul 6, 2016·British Journal of Cancer·Vishwajith SridharanJonathan D Schoenfeld
Dec 13, 2017·Oncotarget·Xinxin Zhu, Jinghe Lang
Dec 20, 2018·Cancer Immunology, Immunotherapy : CII·Nadia B HassounahEsra A Akbay
Oct 27, 2017·Expert Review of Molecular Diagnostics·Paul Hofman
Jan 23, 2020·Nature Reviews. Immunology·Dhouha DaassiGordon J Freeman
Jun 19, 2018·Frontiers in Pharmacology·Yiting WangJie Xu
Oct 25, 2017·Cancer Biomarkers : Section a of Disease Markers·Rong-Miao ZhouBao-En Shan
Nov 2, 2019·Critical Reviews in Oncology/hematology·Taher Abu HejlehGerald Clamon
Feb 2, 2021·Frontiers in Immunology·Marta WagnerLidia Karabon
Jun 27, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Honggang YingXueli Bai

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
genotyping
enzyme-linked immunosorbent assay

Software Mentioned

SPSS

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.